Sagimet's $115M raise funds denifanstat acne Phase 3 through its 2027 readout and beyond
The US biotech has begun enrolling its American late-stage acne study and says October's financing leaves it funded past the expected data release.
Sagimet Biosciences has secured the money to see its lead asset through a pivotal US readout. A $115M financing closed in October, and the company puts its pro forma cash at roughly $356M. It expects that to cover operations until mid-2029, later than the date it anticipates topline results from its American Phase 3 acne programme.
The study, called AURORA, tests denifanstat in moderate to severe acne. Sagimet said in a November 2026 corporate presentation that dosing began in October, and that topline data are expected in the second half of 2027. A US filing for the acne indication would depend on those results.
Outside the US, the drug's partner Ascletis has already filed in China. According to the presentation, the National Medical Products Administration accepted its new drug application for acne in December 2025. This is the first regulatory filing for denifanstat in this indication. The material provided gives no timeline for a decision.
Sagimet is also widening its work on fatty acid synthase (FASN) inhibition. It plans to begin a Phase 2 acne trial of TVB-3567, a follow-on compound, by the end of 2026. Further development in metabolic dysfunction-associated steatohepatitis (MASH) is conditional on non-dilutive funding, the company said, so that work does not rely on the new cash.
Why it matters
- The financing covers the company beyond the expected AURORA readout, so the pivotal data should not force a near-term raise.
- The 2H 2027 readout is the next major clinical value inflection for denifanstat in acne, and a US filing hinges on it.
- China is the earliest regulatory test: Ascletis's acne application has been accepted, but no decision date has been disclosed.
- MASH development now waits on outside, non-dilutive funding, while TVB-3567 in acne is the next FASN programme to enter the clinic.
Company's press release (SEC filing): Sagimet Biosciences Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
